

GP Educational Webinar Abnormal haematology blood tests: when to worry and when to refer Mamta Sohal Consultant Haematologist Imperial College Healthcare NHS Trust



Patient focused

Collaborative Expert

Caring

Talk outline

- Red cells
 - Anaemia
 - Polycythaemia
- White cells
 - Leukaemias acute & chronic
- Platelets
 - Thrombocytosis
 - Thrombocytopenia
- Paraproteins





General Considerations 1



Clinical Context

eg well / sick patient, pregnant, sepsis etc

• Historical Data

eg duration, trends

Co-morbidities

incl drugs or recent changes

Technical issues

eg difficult phlebotomy, aged sample, contamination

General Considerations 2



North West London Pathology

• Age, Sex, Ethnicity

• Normal ranges

• 1 or more lineage abnormalities

Hb	Neuts
g/l	x10 ⁹
140-230	2.7-14
94-130	0.7-4.8
101-130	1 - 8
130-168 114-150	2.0 –7.1
	g/l 140-230 94-130 101-130 130-168



Beta Thalassaemias



- Beta thal trait
- Slightly reduced Hb disproportionately low MCV elevated RBC
- Raised Hb A₂

Alpha Thalassaemias

- Alpha plus trait is the commonest monogenic disorder in the world.
- ¼ of individuals with African ancestry are heterozygous for alpha plus (-a/aa) while 1-2% are homozygotes (-a/-a)
- Clinically silent

Alpha o trait



- (--/aa)
- South east asia, Mediterranean
- Mild anaemia MCV and MCH reduced
- Blood film microcytosis and hypochromia
- MCH usually < 25pg







Case 1



• A 2 year old girl is referred to the paediatric haematology clinic with anaemia and lethargy. She is a picky eater and drinks mainly milk.

Case 1



- Hb 45g/l
- MCV 55 fl
- WBC 6.3 x 10⁹/l
- Neuts 4.9 x 10⁹/l
- Plts 134 x 10⁹/l











Iron Economy

North West London Pathology



With permission from Pietrangelo A. N Engl J Med. 2004;350:2383-2397.



Investigations



Red cells: Anaemia



	MCV	Ferritin	TIBC	Serum Fe	Transferrin sats
Iron Deficiency	Usually low, trend important	↓ confirmatory but may be n or ↑	High	Low	Reduced once tissue stores deplete
Anaemia of chronic disease	Normal or low	Usually normal or \uparrow	Normal or ↓	Normal or ↓	
Thalassaemia	Normal or reduced	Normal or ↑			

Management



• Fe available in diet, tablet, liquid, IV and IM



Oral Fe preparations



Fe preparation	Fe content
Ferrous fumerate	65mg elemental Fe per 200mg
Ferrous sulphate	65mg elemental Fe per 200mg
Ferrous gluconate	35mg elemental iron per 300mg



Parenteral Fe

North West London Pathology

	Cosmofer Fe dextran	Venofer Fe sucrose	Ferinject Fe carbomaltos e	Monofer Fe isomaltoside
Dose	50mg/ml	20mg/ml	50mg/ml	100mg/ml
Test dose	Yes each infusion	First dose only	No	No
Route	IV	IV	IV	IV
Able to administer total dose	Yes	No	Yes	Yes
In preg	CI first trimester	CI first trimester	CI first trimester	CI first trimester
Adverse reactions	5% minimal adverse reactions	0-1.5%	3%	1%

North West London Pathology



Iron deficiency: when to refer



- For consideration of IV iron
 - Unable to tolerate oral iron
 - Persistent Fe deficiency despite oral iron
 - Symptomatic / clinically significant anaemia
 - Who you refer to depends on underlying cause

Case 2



 A 35 year old lady with a history of hypothryoidism presents with increasing lethargy despite normal TFTs. On examination she appears slightly jaundiced.

Case 2



- Hb 72g/l
- MCV 117 fl
- WBC 5.5 x10⁹/l
- Neut 3.5 x 10⁹/l
- Plt $150 \times 10^{9}/l$









RED CELL FOLATE

150 - 850

Red cell folate * 68 ug/L

B12 ASSAY

B12 assay * 93 ng/L 160 - 800 Deficient <160 ng/L Very low B12. Please load the patient with Intramuscular Vit B12 and re-check after a month

B12 deficiency



- B12 measures inactive (TC I and TCIII now known as halohaptochorrin and active forms TCII – halotranscobalamin)
- Not always clear cut
- Homocysteine levels and MMA levels

Fig 1 Mechanism of dietary vitamin B12 absorption.







Fig 2 Clinical features of vitamin B12 deficiency.

North West London Pathology



Hunt A et al. BMJ 2014;349:bmj.g5226



North West London Pathology

Investigations

Assessment	Finding	Major limitations/ comments
Physiological		
MCV	Normal or increased (>100fl)	Poor specificity may be normal in co existing Fe def or thal
Hb	Normal or low	Poor Spec and sens
Retic	Low	Poor spec
LDH	Increased	Intramedullary haemolysis
Blood film /BM	See slide	
Static		
cobalamin	Low (<160ng/l) < 70ng/ml if pregnant)	Not highly specific. Normal levels in some deficient patients. Insensitive to inborn errors of metaboolism. Slight to moderate low levels may not reflect deficiency
halotranscobalamin	Low (<5pm/l), replete (>50pmol/l), intermediate (25-50pmol/l)	Not widely available
Functional		
Plasma MMA	Increased (>350nmol/l)	Increased in renal failure and older people
Plasma homocysteine	Raised (>15)	Increased in folate and B ₆ deficiencies, renal failure , hypothyroidism

Management



- A therapeutic trial can confirm the diagnosis
- Hb rises within 10 days and usually returns to normal at 8 weeks
- Hypersegmented neutrophils disappear around 10-14 days
- Watch K+ levels in severely anaemic patients
- Neurological abnormalities slower to improve and can take months
- Parenteral B12 1mg three times a week for two weeks and then every 3 months
- Oral B12 if dietary deficiency
- Remember levels drop in Pregnancy.

North West London Pathology



Anaemia in the Elderly



- Incidence in > 65 years 11% and 10% for men and women respectively
- 1/3 nutritional deficiencies
- 1/3 anaemia of inflammation
- 1/3 unexplained

Anaemia of the elderly



- Increased epo resistance
- Increased proinflammatory cytokine

Anaemia of the elderly



- Haematinics
- Autoantibodies
- Haemolysis screen
- Myeloma screen
- Consider BM

Case 3



- A GP blood count comes through with no clinical details.
- Hb 135g/l
- WBC 6.3 x 10⁹/I
- Neuts 4.9 x 10⁹/l
- Plts 10x 10⁹/l



Case 3



Platelets



• Low	Technical	Clot / Clumping
Platelets	Temporary	Reactive, post viral
	Persistent	eg drugs, EtOH, liver disease, infections (Hep B, C,HIV), chronic ITP
	Progressive	BM problems
Immune thrombocytopenia (ITP)



An autoimmune condition characterized by an isolated low platelet count (<100) in the absence of other underlying causes

- Newly diagnosed (< 3 months)
- **Persistent** (3-12 months)
- Chronic (> 12 months)



Pathology of ITP







Is there a platelet count at which serious bleeding occurs?





Distribution of bleeding adverse events by severity and platelet count in both treatment groups in the phase 3 studies. Each point represents one bleeding adverse event. One grade 1 bleeding adverse event that occurred at a platelet count of $505 \times 10^9 L^{-1}$ is not shown **Gernsheimer, JTH 2010**

Management goal: hemostatically active platelet count (usually 30-50K) with minimal side effects



Case 4



- 78 year old lady presented feeling TATT . Her results were
- Hb 105g/l
- MCV 110fl
- WBC 6.3 x 10⁹/I
- Neuts 4.9 x 10⁹/l
- Plts 160 x 10⁹/l

• Two months later

- Hb 75g/l
- MCV 110fl
- WBC 4.3 x 10⁹/l
- Neuts 0.9 x 10⁹/l
- Plts 50 x 10⁹/l

Blood film



Case 5



- 35 year old woman presents with feeling tired and a bit dizzy
- Hb 95g/l
- MCV 84fl
- WBC 283x 10⁹/I
- Neuts 200x 10⁹/l
- Plts 175 x 10⁹/l

North West What is the diagnosis? **London Pathology**

NHS



CML- Cytogenetics



The abnormality seen by Nowell & Hungerford on chromosome 22, Now known as the Philadelphia Chromosome.

SIGNALING

Normal Bcr-Abl Signaling

Bcr-Abl

ADP

PP

- The kinase domain activates a substrate protein (eg, PI3 kinase) by phosphorylation
- This activated substrate initiates a signaling cascade culminating in cell proliferation and survival

ADP = adenosine diphosphate; ATP = adenosine triphosphate; P = phosphate.

Savage DG, Antman KH. N Engl J Med. 2002;346:683-693. Scheijen B, Griffin JD. Oncogene. 2002;21:3314-3333.



Imatinib Mesylate: Mechanism of Action

- Imatinib mesylate occupies the ATP binding pocket of the Abl kinase domain
- This prevents substrate phosphorylation and signaling
- A lack of signaling inhibits proliferation and survival









- A 20 year old rugby player prone to injury presented with a dislocated shoulder
- Hb 135g/l
- MCV 84fl
- WBC 15x 10⁹/l
- Neuts 9 x 10⁹/l
- Plts 700 x 10⁹/l



What is the diagnosis ?



Source: Lichtman MA, Kipps TJ, Seligsohn U, Kaushansky K, Prchal JT: Williams Hematology, 8th Edition: http://www.accessmedicine.com Copyright © The McGraw-Hill Companies, Inc. All rights reserved.



Case 7



- A 75 year old gentleman comes for a routine check . Other than hypertension he is fit and well.
- Hb 135g/l
- MCV 84fl
- WBC 30x 10⁹/I
- Neuts 5 x 10⁹/l Lymp 20 x 10⁹/l
- Plts 400 x 10⁹/l



What is the diagnosis?



CLL

- Most common type of chronic leukaemia
- Mostly occurs in those >60
- No cure but a very slowly progressing disease
- 50% diagnosed incidentally on a routine blood test
- Most patients die with it rather than of it
- Active monitoring for a large proportion

CLL- when to treat



- Rapidly rising WBC
- B symptoms- weight loss, drenching sweats
- Bulky lymphadenopathy
- Bone marrow failure



MGUS – monitoring



• Purpose is to identify transformation to a malignant disorder (eg myeloma, WM) at an early stage

	NW London Out	patient Pathways	
	15. Paraproteinaemia (1 of 2)		V1 / 9/7/20
Waldenströms macroglobulinaemia. Parapr MGUS is a diagnosis of exclusion: 3% of ov not associated with symptoms or physical fi time.	oteins may also be a feature of Cl er-50s, 5% of over 70s and 7.5% ndings. The overall risk of MGUS made for patients with raised i	of over 85s have paraproteins which are frequer progression to myeloma is around 1% per year - mmunoglobulin levels in the absence of a mo	tly found incidentally and this remains constant over
Risk Group	20 year risk of progression to myeloma (%)	Serum Free Light Chains Light chains can be elevated in a variety of c	onditions
Low Risk Serum Paraprotein <15g/l IgG isotype Appropriate FLC ratio	5%	 Both kappa and lambda light chains will be raised in renal failure Please repeat one off borderline abnormalities Please refer if the kappa or lambda light chains are > 200mg/ml If the light chain ratio is clearly abnormal, i.e. >4 or < 0.25 the patient should be referred to a myeloma clinic (2 week wait). Renal impairment may lead to an increased serum FLC ratio. The proposed sFLC ratio reference range for these patients is 0.37-3.10 Please note that the free light chain assay is not a substitute for other laboratory evaluations such as protein electrophoresis. 	
Low-Intermediate Risk Presence of an IgA or IgM isotype (NB: Paraprotein must be less than 10g/I) OR Inappropriate FLC ratio	21%		
High-intermediate Risk Presence of an IgA or IgM istotype (NB: Paraprotein must be less than 10g/l) AND Inappropriate FLC ratio	37%		
High Risk If IgG, Paraprotein >15g/l If IgA or IgM, Paraprotein >10g/l Inappropriate FLC ration	58%		

Monitoring in primary care



- M protein at levels below in whom there are no symptoms, signs or results of initial investigations suggestive of myeloma, LPD, or AL amyloidosis
- IgG M protein <15g/l
- IgA or IgM < 10g/l
- This forms the vast majority of M proteins detected in routine practise



Useful links



- NWL CCG GP Haematology guidelines: <u>https://www.nwlondonccgs.nhs.uk/prof</u> <u>essionals/referral-guidelines-and-clinical-</u> <u>documents/haematology</u>
- Imperial GP Haematology email advice line: <u>haematologyadvice.imperial@nhs.net</u>